Lantern Pharma Receives Notice Of U.S. Patent Allowance For Drug Candidate LP-184 For The Treatment Of Rare Pediatric Brain Cancer, ATRT
Portfolio Pulse from Happy Mohamed
Lantern Pharma Inc. (NASDAQ:LTRN) has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for its drug candidate LP-184, developed for the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT), a rare pediatric brain cancer. LP-184 is the first drug developed using Lantern's AI and machine learning platform, RADR®. The FDA has previously granted LP-184 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of pediatric patients with ATRT. The aggregate annual market potential of LP-184's target indications is estimated to be approximately $10+ billion.
August 14, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma's receipt of a patent allowance for LP-184 could potentially boost the company's stock in the short term. The drug's market potential is estimated to be over $10 billion annually.
The receipt of a patent allowance for LP-184 strengthens Lantern Pharma's intellectual property portfolio and provides additional protection for the drug, which is being developed for multiple targeted oncology indications. This could potentially attract more investors to the company, leading to a rise in its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100